Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Share Class Description:
LLY: Ordinary SharesTotal Employee Number:
50,000Compare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.ArgentinaLLY.GermanyLLY.Mexico1LLY.ItalyLLYC.AustriaLLYCL.ChileLLY.SwitzerlandLLY.BulgariaLILY.Poland0Q1G.UK Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1970-07-09Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 1.62 | |||||
Debt-to-EBITDA | 1.27 | |||||
Interest Coverage | 56.06 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 7.89 | |||||
Beneish M-Score | -1.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.9 | |||||
3-Year EBITDA Growth Rate | 54.4 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 9.3 | |||||
3-Year Book Growth Rate | 38.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.94 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.29 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.82 | |||||
9-Day RSI | 64.52 | |||||
14-Day RSI | 60.71 | |||||
3-1 Month Momentum % | 25.32 | |||||
6-1 Month Momentum % | 15.96 | |||||
12-1 Month Momentum % | 89.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1 | |||||
Cash Ratio | 0.19 | |||||
Days Inventory | 376.79 | |||||
Days Sales Outstanding | 79.31 | |||||
Days Payable | 137.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.52 | |||||
Dividend Payout Ratio | 0.21 | |||||
3-Year Dividend Growth Rate | 15.2 | |||||
Forward Dividend Yield % | 0.56 | |||||
5-Year Yield-on-Cost % | 1.06 | |||||
3-Year Average Share Buyback Ratio | 2 | |||||
Shareholder Yield % | 0.18 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.4 | |||||
Operating Margin % | 49.72 | |||||
Net Margin % | 33.53 | |||||
EBITDA Margin % | 54.36 | |||||
FCF Margin % | 17.02 | |||||
OCF Margin % | 35.25 | |||||
ROE % | 99.91 | |||||
ROA % | 22.74 | |||||
ROIC % | 37.36 | |||||
3-Year ROIIC % | 35.59 | |||||
ROC (Joel Greenblatt) % | 113.32 | |||||
ROCE % | 53.04 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 40.77 | |||||
Forward PE Ratio | 34.55 | |||||
PE Ratio without NRI | 38.58 | |||||
Shiller PE Ratio | 121.87 | |||||
Price-to-Owner-Earnings | 64.15 | |||||
PEG Ratio | 1.26 | |||||
PS Ratio | 13.64 | |||||
PB Ratio | 32.05 | |||||
Price-to-Tangible-Book | 156.98 | |||||
Price-to-Free-Cash-Flow | 80.35 | |||||
Price-to-Operating-Cash-Flow | 38.81 | |||||
EV-to-EBIT | 27.4 | |||||
EV-to-Forward-EBIT | 29.03 | |||||
EV-to-EBITDA | 26.07 | |||||
EV-to-Forward-EBITDA | 26.97 | |||||
EV-to-Revenue | 14.17 | |||||
EV-to-Forward-Revenue | 13.13 | |||||
EV-to-FCF | 83.26 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 12.6 | |||||
Price-to-DCF (Earnings Based) | 1.49 | |||||
Price-to-DCF (FCF Based) | 5.25 | |||||
Price-to-Median-PS-Value | 1.7 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.54 | |||||
Price-to-Graham-Number | 16.4 | |||||
Earnings Yield (Greenblatt) % | 3.65 | |||||
FCF Yield % | 1.25 | |||||
Forward Rate of Return (Yacktman) % | 20.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:LLY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 79,665.8 | ||
| EPS (TTM) ($) | 29.8 | ||
| Beta | 0.4456 | ||
| 3-Year Sharpe Ratio | 0.94 | ||
| 3-Year Sortino Ratio | 1.82 | ||
| Volatility % | 36.08 | ||
| 14-Day RSI | 60.71 | ||
| 14-Day ATR ($) | 42.648234 | ||
| 20-Day SMA ($) | 1173.659 | ||
| 12-1 Month Momentum % | 89.98 | ||
| 52-Week Range ($) | 625.9 - 1249.45 | ||
| Shares Outstanding (Mil) | 891.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-04 10:00 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-04 | In 177 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 10:00 | In 80 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 79 days | ||
| USD 1.730000 Cash Dividend | 2026-08-14 | In 3 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 10:00 | 1,115.68 (-0.15%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 1,115.68 (-0.15%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 15:20 | 1,149.15 (-0.85%) | ||
| Investor event | 2026-06-06 18:00 | 1,131.42 (-1.01%) | ||
| USD 1.730000 Cash Dividend | 2026-05-15 | 1,006.70 (-1.06%) |
Show
Entries
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(LLY)'s stock price today?
The current price of LLY is $1215.02. The 52 week high of LLY is $1249.45 and 52 week low is $625.90.
When is next earnings date of Eli Lilly and Co(LLY)?
The next earnings date of Eli Lilly and Co(LLY) is 2026-10-29.
Does Eli Lilly and Co(LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(LLY) is 0.52% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(LLY) was 0.72. The lowest was 0.21. And the median was 0.44. The  Forward Dividend Yield % of Eli Lilly and Co(LLY) is 0.56%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:LLY
Press Release
Articles on Eli Lilly and Co
Headlines
See More- 1
Aug 11, 2026
Eli Lilly’s weight-loss pill gets first European approval in U.K.
Seeking Alpha • 3:23am
Aug 08, 2026
Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Seeking Alpha • 10:15am
Aug 07, 2026
Lilly, Novo antitrust case over GLP-1s dismissed in Texas
Seeking Alpha • 10:08am
Aug 05, 2026
Lilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market
Seeking Alpha • 1:48pm
CVS Health expands GLP-1 offerings with Lilly
Seeking Alpha • 7:08am
Aug 03, 2026
4 stocks to watch on Monday: MAR, LLY, TSN, and PTON
Seeking Alpha • 8:05am
Aug 02, 2026
Notable healthcare headlines for the week: Curium, Bristol-Myers Squibb, and Johnson & Johnson in focus
Seeking Alpha • 8:05am
Aug 01, 2026
Earnings scorecard: eight out of nine healthcare companies deliver EPS wins this week
Seeking Alpha • 12:00pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers